- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 729-743 of
973 results
2509 Exhibit: EX2509 Novo Nordisk, Financial report for the period 1 January 2021...
Document
IPR2023-00724, No. 2509 Exhibit - EX2509 Novo Nordisk, Financial report for the period 1 January 2021 to 31 December 2021 Feb 2, 2022 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2404 Exhibit: EX2404 US Food Drug Administration, DrugsFDA, Onglyza®
Document
IPR2023-00724, No. 2404 Exhibit - EX2404 US Food Drug Administration, DrugsFDA, Onglyza® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2469 Exhibit: EX2469 US Food Drug Administration, DrugsFDA, Stegluromet
Document
IPR2023-00724, No. 2469 Exhibit - EX2469 US Food Drug Administration, DrugsFDA, Stegluromet (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2015 Exhibit: EX2015 Shaman, A, et al, “Effect of the Glucagon Like Peptide 1 Rec...
Document
IPR2023-00724, No. 2015 Exhibit - EX2015 Shaman, A, et al, “Effect of the Glucagon Like Peptide 1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2...
|
|
Cite Document
2519 Exhibit: EX2519 Gorgojo Martínez, JJ, et al, Clinical Recommendations to Ma...
Document
IPR2023-00724, No. 2519 Exhibit - EX2519 Gorgojo Martínez, JJ, et al, Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp 1 Receptor Agonists...
|
|
Cite Document
2374 Exhibit: EX2374 Tran, KL, et al, Overview of Glucagon Like Peptide 1 Recept...
Document
IPR2023-00724, No. 2374 Exhibit - EX2374 Tran, KL, et al, Overview of Glucagon Like Peptide 1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes, Am Health Drug Benefits...
|
|
Cite Document
2447 Exhibit: EX2447 US Food Drug Administration, DrugsFDA, Trulicity®
Document
IPR2023-00724, No. 2447 Exhibit - EX2447 US Food Drug Administration, DrugsFDA, Trulicity® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2101 Exhibit: EX2101 Marso, SP, et al, Semaglutide and Cardiovascular Outcomes...
Document
IPR2023-00724, No. 2101 Exhibit - EX2101 Marso, SP, et al, Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, N Engl J Med, 3751834 1844 2016 (P.T.A.B. Jan. 17, ...
|
|
Cite Document
2497 Exhibit: EX2497 Novo Nordisk, Financial report for the period 1 January 2018...
Document
IPR2023-00724, No. 2497 Exhibit - EX2497 Novo Nordisk, Financial report for the period 1 January 2018 to 31 December 2018 Feb 1, 2019 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2445 Exhibit: EX2445 Trulicity® Prescribing Information rev Aug 2017
Document
IPR2023-00724, No. 2445 Exhibit - EX2445 Trulicity® Prescribing Information rev Aug 2017 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2365 Exhibit: EX2365 US Food Drug Administration, DrugsFDA, Amaryl®
Document
IPR2023-00724, No. 2365 Exhibit - EX2365 US Food Drug Administration, DrugsFDA, Amaryl® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2443 Exhibit: EX2443 US Food Drug Administration, DrugsFDA, Invokamet®
Document
IPR2023-00724, No. 2443 Exhibit - EX2443 US Food Drug Administration, DrugsFDA, Invokamet® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2053 Exhibit: EX2053 Declaration of Smita Agarwal
Document
IPR2023-00724, No. 2053 Exhibit - EX2053 Declaration of Smita Agarwal (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2427 Exhibit: EX2427 US Food Drug Administration, DrugsFDA, Nesina®
Document
IPR2023-00724, No. 2427 Exhibit - EX2427 US Food Drug Administration, DrugsFDA, Nesina® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2105 Exhibit: EX2105 Nauck, MA, et al, Cardiovascular Actions and Clinical Outcom...
Document
IPR2023-00724, No. 2105 Exhibit - EX2105 Nauck, MA, et al, Cardiovascular Actions and Clinical Outcomes With Glucagon Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibito...
|
|
Cite Document
